BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

NOXXON Pharma AG 

Max-Dohrn-Strasse 8-10

Berlin    10589  Germany
Phone: 49-30-726247-0 Fax: 49-30-726247-225


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical

Segment
Drug Discovery





 Company News
NOXXON Pharma AG Presents Updates On Phase II Studies With Olaptesed Pegol (NOX-A12) In CLL And MM And Lexaptepid Pegol (NOX H94) In Anemic Cancer Patients 6/13/2014 9:55:04 AM
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014 10:45:37 AM
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014 9:30:45 AM
NOXXON Pharma AG Presents Positive Results From Emapticap Pegol Phase 2a Diabetic Nephropathy Study 4/4/2014 7:14:02 AM
NOXXON Pharma AG Release: Interim Phase IIa Results For Spiegelmer Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013 10:25:13 AM
NOXXON Pharma AG Release: Interim Phase 2a Results For Spiegelmer® Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013 9:57:27 AM
NOXXON Pharma AG Completes Patient Recruitment for Phase 2 Study in Diabetic Nephropathy 7/24/2013 9:49:18 AM
Two Posters and Two Oral Presentations on NOXXON Pharma AG Compounds at 2012 American Society of Hematology Conference 12/6/2012 10:57:53 AM
NOXXON Pharma AG Initiates Phase IIa of Anti-Hepcidin Spiegelmer® NOX-H94 12/4/2012 10:45:45 AM
NOXXON Pharma AG Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer® 9/26/2012 9:29:10 AM
1234